Tanya B. Dorff, MD, on Results From Phase 1 CAR T-Cell Therapy mCRPC Trial
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
Assessing the Benefit of CAR T-cell Therapies for mCRPC
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
GTB-3650 Snags FDA Clearance for IND Application in CD33+ Leukemia
Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.
Cilta-cel Improves Survival Vs Standard Therapy in R/R Multiple Myeloma
Second interim analysis findings from CARDITUDE-4 show no new safety signals with cilta-cel in relapsed, lenalidomide-refractory multiple myeloma.
Determining Resectability and Subsequent Therapy in Pancreatic Cancer
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Glofitamab Shows Benefit Regardless of Prior BTK Exposure in R/R MCL
All patient populations benefitted from glofitamab in a phase 1/2 trial, but the design excluded capture of high-risk features present in similar studies.
Investigators Discontinue Development of Envafolimab for Sarcoma
The announcement follows results from the ENVASARC trial, where the primary endpoint needed to support a biologics license application was not met.
BLA Resubmitted for Cosibelimab in Advanced Squamous Cell Carcinoma
Phase 1 data support the application for cosibelimab as a treatment for those with metastatic or locally advanced cutaneous squamous cell carcinoma.
Transvaginal Ultrasounds May Not Detect Endometrial Cancer in Black Women
Tissue biopsy was recommended among Black patients at risk of endometrial cancer over the common ultrasonography triage strategy.
Defining the Attributes of LINACs, IORT in Pancreatic Cancer Care
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
FDA Approves FoundationOne Liquid CDx for Niraparib Combo in BRCA+ mCRPC
In addition to tissue biopsy, a liquid biopsy test can be used to better identify patients who may benefit from niraparib and abiraterone acetate.
Mesenchymal stromal cells with chimeric antigen receptors for enhanced immunosuppression
Researchers at the Mayo Clinic have found that mesenchymal stromal cells engineered with chimeric antigen receptors can enhance immunosuppression in the context of immune-related disorders.
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
In a collaborative effort between 18 centers, researchers have developed a system that effectively stratifies children at the onset of acute graft versus host disease for risk of non-relapse mortality over 6 months.
Nivolumab/Ipilimumab Plus RT Shows Promise in Locally Advanced Rectal Cancer
The EA2201 trial assessed nivolumab plus ipilimumab and short-course radiation therapy for patients with locally advanced rectal cancer.
EU’s CHMP Recommends Odronextamab Approval in Follicular Lymphoma, DLBCL
Findings from ELM-1 and ELM-2 support the positive opinion for odronextamab as a treatment for relapsed/refractory follicular lymphoma and DLBCL.
Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
ASCO Updates Guidelines for CDK4/6 Inhibitor Use in Breast Cancer
The new recommendation update modifies a 2020 ASCO guideline on the selection of optimal adjuvant chemotherapy and targeted therapy for breast cancer.
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
Lunresertib Combo Shows Responses in Advanced Pretreated GI Cancer Subtypes
Phase 1 data may warrant further investigation of lunresertib in high-risk gastrointestinal tumors with CCNE1 amplifications or FBXW7 mutations.
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
Ivonescimab/Chemotherapy Improves PFS in EGFR TKI–Treated NSCLC
The first-in-class tetravalent bispecific antibody may show binding affinity to PD1 and VEGF based on in vitro studies.
Bispecific Antibodies are Helping to Advance the Field of Lymphoma
Julie M. Vose, MD, MBA, and Avyakta Kallam, MD, highlighted research advances in the lymphoma field they’ve witnessed throughout their careers.
EU’s CHMP Recommends Epcoritamab Approval in R/R Follicular Lymphoma
The European Commission is expected to decide on approving epcoritamab in relapsed/refractory follicular lymphoma later in 2024.
Nivolumab Combo Improves HRQOL Vs Chemo in MSI-H/dMMR Metastatic CRC
HRQOL data from the CheckMate 8HW trial may further support frontline nivolumab/ipilimumab for those with MSI-H or dMMR metastatic colorectal cancer.
FDA Approves Novel Formulation for Breast and Ovarian Cancers
A ready-to-dilute formula of SH-105 has been approved by the FDA to treat breast and ovarian cancers.
Acalabrutnib Combo Shows PFS Benefit in Elderly MCL Population
Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.
CAR T-Cell Therapy Demonstrates Promising Results for mCRPC
In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.
FDA Sends CRL for Patritumab Deruxtecan in Advanced EGFR+ NSCLC
The complete response letter for patritumab deruxtecan is based on findings related to a third-party manufacturing site inspection.
Younger Age Improves Pregnancy Prospects After ET Therapy Pause in HR+ Breast Cancer
Updated results from the POSITIVE trial found that patients younger than 35 years had a higher likelihood of achieving pregnancy during an endocrine therapy pause for HR-positive breast cancer.
FDA Grants Accelerated Approval to Epcoritamab in R/R Follicular Lymphoma
Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.
